IBRX - ImmunityBio, Inc.


2.61
-0.080   -3.065%

Share volume: 3,296,891
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.03%

PREVIOUS CLOSE
CHG
CHG%

$2.69
-0.08
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Income statement Balance sheet Cash flow To see more then 2 years history Buy Premium
View ratios

Fiscal Date 03-31-2023 06-30-2023 09-30-2023 12-31-2023 03-31-2024 06-30-2024 09-30-2024 12-31-2024
Fiscal Quarter Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Report Date 05-11-2023 08-08-2023 11-09-2023 03-19-2024 05-09-2024 08-12-2024 11-12-2024 03-03-2025
Total revenue 360.000 K 41.000 K 82.000 K 139.000 K 40.000 K 1.047 M 6.106 M 7.552 M
Cost of revenue 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Gross profit 360.000 K 41.000 K 82.000 K 139.000 K 40.000 K 1.047 M 6.106 M 7.552 M
    -88.61% 100.00% 69.51% -71.22% 2,517.50% 483.19% 23.68%  
Operating expenses 111.940 M 85.186 M 80.218 M 84.642 M 95.236 M 100.380 M 86.359 M 76.952 M
Selling general and admin 32.676 M 32.018 M 31.816 M 33.110 M 41.885 M 49.251 M 35.916 M 41.731 M
Research and development 79.264 M 53.168 M 48.402 M 51.532 M 53.351 M 51.129 M 50.443 M 35.221 M
Total expenses 114.277 M 89.143 M 81.473 M 84.642 M 95.236 M 100.380 M 86.359 M 76.952 M
    -21.99% -8.60% 3.89% 12.52% 5.40% -13.97% -10.89%  
Operating income -113.917 M -89.102 M -81.391 M -84.503 M -95.196 M -99.333 M -80.253 M -69.400 M
Ebit -113.917 M -89.102 M -81.391 M -84.503 M -99.742 M -97.456 M -47.303 M -22.792 M
Pretax income -116.583 M -138.213 M -95.642 M -233.454 M -134.130 M -134.584 M -85.752 M -59.179 M
    18.55% -30.80% 144.09% -42.55% 0.34% -36.28% -30.99%  
Income tax 0.000 0.000 0.000 -40.000 K 0.000 0.000 0.000 0.000
Net income basic -116.343 M -137.879 M -95.582 M -233.392 M 0.000 0.000 0.000 0.000
    -18.51% 30.68% -144.18% 100.00%        
Net income -116.343 M -137.879 M -95.582 M -233.392 M -134.130 M -134.584 M -85.752 M -59.179 M
    -18.51% 30.68% -144.18% 42.53% -0.34% 36.28% 30.99%